Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, announced today that it has received approval for Salmecort (Salmeterol + Fluticasone) MDI inhaler, from the Ministry of Health, Russia.

The combination preparation contains salmeterol xinafoate and fluticasone propionate, used in the management of asthma and chronic obstructive pulmonary disease (COPD).

The approval is for 25mcg + 50mcg/ dose, 25mcg + 125mcg/dose and 25mcg + 250 mcg/dose formulation strengths.

In addition to generic Seretide, Glenmark has also received a couple of other key product approvals such as Oflomil nail lacquer, which is the first generic of Loceryl in the Russian market and Sertamycol  (sertaconazole) cream in FY 2014-15. The company also launched Kerawort (topical imiquimod, generic of Aldara) in the Russian market in FY 2014-15.

Shares of the company gained Rs 8.1, or 0.97%, to trade at Rs 840. The total volume of shares traded was 27,360 at the BSE (9.35 a.m., Thursday).